v3.26.1
Condensed Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (2,853,575) $ (2,037,436)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 60,909 55,167
Share-based compensation 4,694 55,897
Amendment of warrants 0 48,087
Non-cash settlements 0 58,272
Change in fair value related to warrants and derivative (18) (11,721)
Change in operating assets and liabilities    
Accounts receivable (10,903) (849)
Prepaids and other current assets 20,243 (40,841)
Accounts payable 242,195 (15,334)
Accrued and other liabilities (105,390) (622,024)
Net cash used in operating activities (2,641,845) (2,510,782)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Intangible assets – Patents (49,345) (78,288)
Net cash used in investing activities (49,345) (78,288)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Public offering of common stock and warrants 0 14,554,545
Registered direct offerings of common stock 1,036,000 5,167,927
Proceeds from direct offering of prefunded warrants 9,323,982 0
Common stock cash issuance costs (679,605) (1,959,642)
Exercise of Series C warrants 0 336,441
Redemption of Series B Preferred stock 0 (1,213,590)
Net cash provided by financing activities 9,680,377 16,885,681
Net increase (decrease) in cash and cash equivalents 6,989,187 14,296,611
Cash, cash equivalents and restricted cash, beginning of period 12,040,789 463,661
Cash, cash equivalents and restricted cash, end of period 19,029,976 14,760,272
Supplemental disclosures    
Cash paid for interest 0 0
Cash paid for income taxes 0 0
Non-cash activities    
Capitalization of Series B preferred stock dividends 0 5,425
Capitalization of Series C preferred stock dividends 0 1,258
Conversion of Series C preferred stock to common stock 0 548,534
Cashless exercise of B warrants to common stock $ 0 $ 9,539,081